基本信息
浏览量:107
职业迁徙
个人简介
Christian Klein, Distinguished Scientist, is Department Head Cancer Immunotherapy Discovery 3, Head Oncology Programs & Site Head Roche Innovation Center Zurich, Roche pRED. He specializes in the discovery, engineering, validation and preclinical development of therapeutic/bispecific antibodies for CIT.
During his 22 years at Roche he made essential contributions to the preclinical development & approval of GAZYVA (obinutuzumab, 1st Type II CD20 GlycoMab), project initiation & discovery of VABYSMO (faricimab, 1st BsAb for ophthalmology), discovery & preclinical development of COLUMVI (glofitamab, 1st 2+1 TCB), and preclinical R&D on 26 clinical stage BsAbs, immunocytokines and fusion proteins eg vanucizumab, cibisatamab, simlukafusp alfa, alnuctamab, FAP-4-1BBL, englumafusp alfa, tobemstomig, eciskafusp alfa, forimtamig, trontinemab, CD20-BS, CD19-CD28, RG6382. He lead(s) research teams developing pRED’s BsAb platforms e.g. CrossMab®, 2+1 TCB, 4-1BB/CD28 costimulator, immunocytokine, next gen biologics, P329G-CAR®-T licenced to Innovent, and contributed to research on TEPEZZA (teprotuzumab) and Nutlin MDM2 PPI. Overall, as a drug hunter he contributed to 32 NMEs entering PhI (26 as co-inventor) of which GAZYVA, VABYSMO, COLUMVI, TEPEZZA are approved (cum sales >16 bio) and 10 in active development, and to collaborations with Chugai, Affitech, Engmab, OranoMed, Immatics, Pieris, GoTx, Innovent, NimbleTx and the acquisition of GoodTx.
He contributed to >215 publications, 240 patent families, acts as associate editor of mAbs, antibodies, Fonc, Fimmu and Successful Drug Discovery, and co-organized Keystone's Antibodies as Drugs Symposium 2019 and GBM‘s Mosbacher Kolloquium Immune Engineering 2023. He received the Drug Discovery of the Year 2015 award by the British Pharmacological Society, the pRED leadership medal, multiple Roche pRED, three Roche Awards of Excellence and five Inventors’ Gold Medal awards.
During his 22 years at Roche he made essential contributions to the preclinical development & approval of GAZYVA (obinutuzumab, 1st Type II CD20 GlycoMab), project initiation & discovery of VABYSMO (faricimab, 1st BsAb for ophthalmology), discovery & preclinical development of COLUMVI (glofitamab, 1st 2+1 TCB), and preclinical R&D on 26 clinical stage BsAbs, immunocytokines and fusion proteins eg vanucizumab, cibisatamab, simlukafusp alfa, alnuctamab, FAP-4-1BBL, englumafusp alfa, tobemstomig, eciskafusp alfa, forimtamig, trontinemab, CD20-BS, CD19-CD28, RG6382. He lead(s) research teams developing pRED’s BsAb platforms e.g. CrossMab®, 2+1 TCB, 4-1BB/CD28 costimulator, immunocytokine, next gen biologics, P329G-CAR®-T licenced to Innovent, and contributed to research on TEPEZZA (teprotuzumab) and Nutlin MDM2 PPI. Overall, as a drug hunter he contributed to 32 NMEs entering PhI (26 as co-inventor) of which GAZYVA, VABYSMO, COLUMVI, TEPEZZA are approved (cum sales >16 bio) and 10 in active development, and to collaborations with Chugai, Affitech, Engmab, OranoMed, Immatics, Pieris, GoTx, Innovent, NimbleTx and the acquisition of GoodTx.
He contributed to >215 publications, 240 patent families, acts as associate editor of mAbs, antibodies, Fonc, Fimmu and Successful Drug Discovery, and co-organized Keystone's Antibodies as Drugs Symposium 2019 and GBM‘s Mosbacher Kolloquium Immune Engineering 2023. He received the Drug Discovery of the Year 2015 award by the British Pharmacological Society, the pRED leadership medal, multiple Roche pRED, three Roche Awards of Excellence and five Inventors’ Gold Medal awards.
研究兴趣
论文共 321 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Alexandra Florescu,Michelle Zuo,Angela A Wang,Kevin Champagne-Jorgensen, Mohammed A Noor,Lesley A Ward,Erwin van Puijenbroek,Christian Klein, Jen Gommerman
biorxiv(2024)
Nature Reviews Drug Discoveryno. 4 (2024): 1-19
Estelle Marrer-Berger,Annalisa Nicastri,Angelique Augustin, Vesna Kramar,Hanqing Liao,Lydia Jasmin Hanisch,Alejandro Carpy,Tina Weinzierl,Evelyne Durr,Nathalie Schaub,Ramona Nudischer,Daniela Ortiz-Franyuti,Ekaterina Breous-Nystrom,Janick Stucki,Nina Hobi,Giulia Raggi,Lauriane Cabon,Emmanuelle Lezan,Pablo Umana,Isaac Woodhouse,Alexander Bujotzek,Christian Klein,Nicola Ternette
Nature communicationsno. 1 (2024)
Leukemia (2024)
Molecular pharmaceuticsno. 8 (2023): 4319-4330
pubmed(2023)
Ivana Spasevska,Eva Laure Matera,Kamel Chettab, Jade Ville,Marie Potier-Cartereau,Lars Petter Jordheim, Catherine Thieblemont,Denis Sahin,Christian Klein,Charles Dumontet
pubmed(2023)
Miles Piper,Maureen Hoen,Laurel B. Darragh,Michael W. Knitz,Diemmy Nguyen,Jacob Gadwa,Greta Durini, Idil Karakoc, Abby Grier,Brooke Neupert,Benjamin Van Court,Khalid N. M. Abdelazeem,Justin Yu,Nicholas A. Olimpo,Sophia Corbo,Richard Blake Ross,Tiffany T. Pham,Molishree Joshi,Ross M. Kedl,Anthony J. Saviola,Maria Amann,Pablo Umana,Laura Codarri Deak,Christian Klein,Angelo D'Alessandro,Sana D. Karam
CANCER CELLno. 5 (2023)
加载更多
作者统计
#Papers: 323
#Citation: 17343
H-Index: 54
G-Index: 129
Sociability: 7
Diversity: 4
Activity: 236
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn